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Statins are well-tolerated cholesterol lowering drugs.
However, in rare cases myotoxicity or even rhabdomyoly-
sis occur. We have recently shown that in vitro statins are
able to induce apoptosis in differentiated human skeletal
muscle cells. In particular, simvastatin triggers the mito-
chondrial pathway of apoptosis via translocation of Bax
from the cytosol to the mitochondrial membrane. Accord-
ingly, caspase 9 and caspase 3 were consecutively acti-
vated. Here we show that an early event in simvastatin
action is up-regulation of RhoB on mRNA level which is
paralleled by the downstream Krüppel-like factor-2 (KLF-
2) and KLF-6. Moreover, the level of active, GTP-bound
RhoB was increased in simvastatin-treated cells in a con-
centration-dependent manner as determined by Rhotekin
pull-down assay. Up-regulation of RhoB on mRNA and
protein level was dependent on HMG-CoA reductase inhi-
bition. Interestingly, the up-regulation of RhoB was paral-
leled by caspase 2 activation, which might be directly
associated with RhoB and therefore be required for the
cytotoxic effect of simvastatin.
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